Royal London Asset Management Ltd. lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 1.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 894,748 shares of the biopharmaceutical company’s stock after selling 8,854 shares during the period. Royal London Asset Management Ltd.’s holdings in Bristol Myers Squibb were worth $51,555,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth $25,000. Davis Asset Management L.P. acquired a new position in Bristol Myers Squibb in the second quarter valued at about $27,000. Bayban bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $31,000. Finally, Addison Advisors LLC bought a new stake in Bristol Myers Squibb during the second quarter worth about $32,000. Institutional investors own 76.41% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on BMY shares. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. UBS Group cut Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Guggenheim reaffirmed a “buy” rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average price target of $66.06.
Insider Transactions at Bristol Myers Squibb
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.05% of the company’s stock.
Key Stories Impacting Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
- Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
- Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
- Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
- Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
- Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares
Bristol Myers Squibb Stock Performance
NYSE:BMY opened at $66.62 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The stock’s 50-day moving average is $61.76 and its 200-day moving average is $59.68. The stock has a market cap of $136.09 billion, a P/E ratio of 14.67, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
